FTC settlement frameworks for major PBMs mandate transparency to plan sponsors, fee-based remuneration, limits on spread ...

The renewed debate over Most Favored Nation (MFN) drug pricing in the United States reflects a legitimate frustration: ...

In 2015, the first biosimilar (Zarxio; Sandoz) was launched in the United States (US), providing an alternative to the originator product Neupogen (filgrastim; Amgen) for the treatment of severe ...

The authors argue that sustainable drug pricing reform should focus on patient-centered value, not price alone. IRP is a government price-control mechanism utilized worldwide, where a country ...

This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.